WINTON GROUP Ltd Has $1.45 Million Stock Position in Krystal Biotech, Inc. $KRYS

WINTON GROUP Ltd lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 28.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,874 shares of the company’s stock after selling 2,338 shares during the quarter. WINTON GROUP Ltd’s holdings in Krystal Biotech were worth $1,448,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bessemer Group Inc. lifted its stake in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the last quarter. Sound Income Strategies LLC grew its position in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares during the last quarter. Danske Bank A S acquired a new position in Krystal Biotech in the 3rd quarter worth about $35,000. Global Retirement Partners LLC increased its holdings in Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares in the last quarter. Finally, MAI Capital Management raised its position in Krystal Biotech by 79.7% in the third quarter. MAI Capital Management now owns 284 shares of the company’s stock valued at $50,000 after purchasing an additional 126 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KRYS has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $310.00 price target on shares of Krystal Biotech in a research note on Monday, June 1st. Chardan Capital upped their price objective on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Jefferies Financial Group lifted their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Price Performance

Shares of KRYS opened at $301.76 on Tuesday. Krystal Biotech, Inc. has a 1 year low of $127.99 and a 1 year high of $319.48. The company has a market capitalization of $8.90 billion, a price-to-earnings ratio of 40.34 and a beta of 0.53. The business has a 50-day moving average of $283.40 and a 200-day moving average of $265.26.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Insider Buying and Selling

In related news, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.